Core Viewpoint - The company has successfully developed a complete synthetic process chain for key intermediates from toluene, ensuring self-sufficiency and stable supply for its products through innovative continuous production methods [1] Group 1: Production Innovations - The company utilizes advanced production techniques such as continuous tower reaction, continuous kettle reaction, continuous microchannel reaction, continuous tubular reaction, and continuous extraction and distillation, replacing traditional batch production methods [1] - The adoption of large-scale, automated, and continuous production processes has improved labor efficiency and further reduced energy consumption [1] Group 2: Research and Development - The company has accumulated years of independent research and development, leading to the successful synthesis of various key intermediates [1] - Several patented technologies are in use, including methods for producing chlorobenzene and trifluoromethylbenzene through continuous chlorination and fluorination processes [1]

Core Viewpoint - The company aims to enhance its operational performance and management level by expanding its existing product value chain and enriching its product structure, ultimately striving to create value for shareholders [1] Group 1 - The company plans to further expand its existing product value chain [1] - The company intends to enrich its product structure [1] - The company is focused on deepening industry chain collaboration [1] Group 2 - The company is committed to improving operational performance [1] - The company aims to enhance management levels [1] - The company is dedicated to creating value for shareholders [1]

Core Insights - Wihua New Materials successfully completed trial production of multiple high-level intermediates and delivered verification batch orders to multinational companies [1] - Fanghua Chemical has completed the technical reserves for several raw materials and is advancing product design and construction as planned [1] - The company will continue to maintain high levels of R&D investment to extend its product chain, aiming for significant progress in high-level intermediates and raw materials [1]

Core Viewpoint - The company is focusing on expanding its product value through its subsidiary Fanghua Chemical and aims to enhance its market position via acquisitions to strengthen its integrated cost advantages and build competitive barriers [1] Group 1: Investment Projects - Fanghua Chemical's fundraising project primarily involves the production of trifluoromethyl pyridine and trifluoromethyl benzene, which are intermediate products mainly used in the pesticide sector [1] - The company plans to adjust the construction progress of its fundraising projects based on downstream market demand [1] Group 2: Acquisition Strategy - The company announced on August 2, 2025, its intention to acquire a controlling stake in Jiangsu Heyutai Chemical Co., Ltd. through cash transactions by the company or its designated subsidiaries [1] - The acquisition is part of the company's strategy to extend its reach into downstream sectors and enhance its overall industry chain [1]

Core Viewpoint - Wehua New Materials (603310.SH) currently does not have any products in production for mosquito extermination, repelling, or prevention [1] Company Summary - Wehua New Materials has clarified on the investor interaction platform that it does not possess any products aimed at mosquito control [1]

Core Viewpoint - Wihua New Materials (603310.SH) has successfully trial-produced multiple high-level intermediates and completed the delivery of verification batch orders with multinational companies [1] Group 1: Product Development - The company has completed the technical reserves for several raw materials at Fanghua Chemical and is advancing the design and construction of related products as planned [1] - The company will continue to maintain high levels of R&D investment to extend its product chain [1] Group 2: Future Prospects - The aim is to achieve significant progress in high-level intermediates and raw materials [1]

Core Viewpoint - Wihua New Materials (603310.SH) has clarified that there is no collaboration with Cambrian [1] Company Summary - Wihua New Materials confirmed on the investor interaction platform that it does not have any related cooperation with Cambrian [1]

Core Viewpoint - Zhejiang Wihua New Materials Co., Ltd. has engaged in a joint investment with its controlling shareholder, Dongyang Yinghua Holdings Co., Ltd., in a private equity fund, marking a significant related party transaction [1][2]. Group 1: Investment Details - The company has committed a capital contribution of 70 million yuan, representing a 7.37% stake in the partnership [1]. - Dongyang Yinghua Holdings has contributed 30 million yuan, accounting for a 3.16% stake in the same partnership [1]. - The private equity fund is named Yangzhou Dinglong Qishun Equity Investment Partnership (Limited Partnership) [2]. Group 2: Fund Management and Compliance - The fund has completed the registration process with the Asset Management Association of China and has obtained the Private Investment Fund Registration Certificate [2]. - The management of the fund is handled by Xi'an Longding Investment Management Co., Ltd., with the custodian being China Merchants Bank Co., Ltd. [2]. - The registration date for the fund is September 8, 2025 [2].

浙江巍华新材料股份有限公司（以下简称"公司"）与控股股东东阳市瀛华 控股有限公司（以下简称"瀛华控股"）共同向扬州鼎龙启顺股权投资合伙企业 （有限合伙）（以下简称"标的基金"）进行投资。其中公司作为有限合伙人以 自有资金的方式认缴出资 7,000 万元，占合伙企业 7.37%的份额。瀛华控股作为 有限合伙人以自有资金的方式认缴出资 3,000 万元，占合伙企业 3.16%的份额。 标的基金的普通合伙人、执行事务合伙人为西安禾盈创业投资有限公司，标的基 金管理人为西安龙鼎投资管理有限公司。本次投资事项构成公司与关联方共同投 资的关联交易，具体内容详见公司于 2025 年 7 月 26 日刊登于上海证券交易所网 站（www.sse.com.cn）上的相关公告《关于与控股股东共同投资暨关联交易的公 告》。 二、对外投资进展情况 近日，公司收到基金管理人通知，该合伙企业已在中国证券投资基金业协会 完成备案手续并取得《私募投资基金备案证明》，备案信息如下： 基金名称：扬州鼎龙启顺股权投资合伙企业（有限合伙） 证券代码：603310 证券简称：巍华新材 公告编号：2025-050 浙江巍华新材料股份有限公司 关于与控股股 ...

Group 1 - The company, Wehua New Materials (603310.SH), primarily produces chlorotoluene and trifluoromethylbenzene series intermediate products [1] - Currently, the company does not have any research and development plans related to innovative drugs [1]